<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04020419</url>
  </required_header>
  <id_info>
    <org_study_id>1810087420</org_study_id>
    <secondary_id>2R01GM095657</secondary_id>
    <nct_id>NCT04020419</nct_id>
  </id_info>
  <brief_title>Natural Berry Extract Treatment of Hemangiomas</brief_title>
  <acronym>Pediaberry</acronym>
  <official_title>Natural Berry Extract Treatment of Hemangiomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of General Medical Sciences (NIGMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized, double-blind, placebo-controlled parallel group study
      evaluating the use of PediaBerry for the treatment of hemangiomas in infants ≤ 4 months of
      corrected gestation age over a 6-month treatment period. Subjects will be followed to age 18
      months. A total of 44 subjects will be PediaBerry group and 22 subjects in the placebo
      control group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PediaBerry™ is a proprietary blend of powdered berry extracts. Placebo: powdered sugar plus
      McCormick Color from Nature Food Colors Berry and Sky Blue powdered food color
      (https://www.mccormick.com/spices-and-flavors/extracts-and-food-colors/food-colors/color-from
      -nature-assorted-food-color ).

      Cream vehicle is mixed with PediaBerry™ or placebo at the time of application.Children will
      receive once daily topical and oral gavage dosing of PediaBerry or placebo.

      The first study visit will take place within 2 weeks of subject recruitment. The subject
      enrollment, consenting and randomization will occur as study visit #0 and will occur in the
      at Riley Hospital or Nationwide Children's Hospital. Data collection will be the same at all
      study visits starting with study visit #1 until the completion of the study. The first dose
      of PediaBerry™ or placebo will be administered prior to completion of study visit #1, and
      will also be given at study visits #2-6. Study visits #2-6 will occur monthly study visits
      until the subject completes 6 months of treatment.Subjects will be weighed and treatment
      doses adjusted accordingly. Study visits #7-11 to watch for signs of rebound hemangioma
      proliferation will occur every other month until age 12 months and then at age 15 and 18
      months. Urine samples, photos and caliper measurements will occur at each study visit. Some
      subjects may have less than 11 study visits depending on the age at the time of subject
      enrollment.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>pilot study to determine effect size for possible FDA phase I/II trial</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>investigational pharmacy will have access to randomization schemes and will package study drug from bulk supplies. All other study team members and participants are blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Decreased Hemangioma Size</measure>
    <time_frame>6 month treatment period</time_frame>
    <description>Decrease in the size of hemangioma &gt; 50%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decreased urinary micro RNA 126 levels</measure>
    <time_frame>6 month treatment period</time_frame>
    <description>Urinary micro RNA 126 levels are analyzed using quantitative polymerase chain reactions</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Hemangioma</condition>
  <arm_group>
    <arm_group_label>Pediaberry group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PediaBerry™ is a proprietary blend powdered berry extracts</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo: powdered sugar plus McCormick Color from Nature Food Colors Berry and Sky Blue powdered food color (https://www.mccormick.com/spices-and-flavors/extracts-and-food-colors/food-colors/color-from-nature-assorted-food-color ).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PediaBerry</intervention_name>
    <description>PediaBerry or placebo will be mixed with a cream vehicle for topical administration or with water for oral administration</description>
    <arm_group_label>Pediaberry group</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children with hemangiomas ≤ 4 months of corrected gestational age

          -  Hemangioma size ≥ 1.5 cm diameter

        Exclusion Criteria:

          -  Children with hemangiomas that threaten the life of the child or development of vital
             structures.

          -  Children who are breast feeding and mother is taking beta blocker medication

          -  Children with previously treated hemangiomas

          -  Congenital hemangiomas - cannot distinguish between rapidly involuting and
             non-involuting congenital hemangiomas

          -  Hemangiomas located in the perineal/diapering area - product will get contaminated or
             wiped off with diapering

          -  Children with food allergies to blueberries or any other kind of berry

          -  Legal guardian unable to provide informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>4 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gayle Gordillo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Mohnacky, RDN</last_name>
    <phone>(317)-278-2715</phone>
    <email>jmohnack@iu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sashwati Roy, PhD</last_name>
    <phone>317-278-2706</phone>
    <email>roysa@iu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Jennifer Mohnacky, RDN</last_name>
      <phone>317-278-2715</phone>
      <email>jmohnack@iu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Tammy Garrett, RN</last_name>
      <phone>(317) 278-0290</phone>
      <email>tjgarret@iupui.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Gayle Gordillo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hoak JC, Warner ED, Cheng HF, Fry GL, Hankenson RR. Hemangioma with thrombocytopenia and microangiopathic anemia (Kasabach-Merritt syndrome): an animal model. J Lab Clin Med. 1971 Jun;77(6):941-50.</citation>
    <PMID>5105323</PMID>
  </reference>
  <reference>
    <citation>Gordillo G, Fang H, Khanna S, Harper J, Phillips G, Sen CK. Oral administration of blueberry inhibits angiogenic tumor growth and enhances survival of mice with endothelial cell neoplasm. Antioxid Redox Signal. 2009 Jan;11(1):47-58. doi: 10.1089/ars.2008.2150.</citation>
    <PMID>18817478</PMID>
  </reference>
  <reference>
    <citation>Gordillo G, Fang H, Park H, Roy S. Nox-4-dependent nuclear H2O2 drives DNA oxidation resulting in 8-OHdG as urinary biomarker and hemangioendothelioma formation. Antioxid Redox Signal. 2010 Apr 15;12(8):933-43. doi: 10.1089/ars.2009.2917.</citation>
    <PMID>19817625</PMID>
  </reference>
  <reference>
    <citation>Gordillo GM, Atalay M, Roy S, Sen CK. Hemangioma model for in vivo angiogenesis: inducible oxidative stress and MCP-1 expression in EOMA cells. Methods Enzymol. 2002;352:422-32.</citation>
    <PMID>12125369</PMID>
  </reference>
  <reference>
    <citation>Gordillo GM, Biswas A, Khanna S, Pan X, Sinha M, Roy S, Sen CK. Dicer knockdown inhibits endothelial cell tumor growth via microRNA 21a-3p targeting of Nox-4. J Biol Chem. 2014 Mar 28;289(13):9027-38. doi: 10.1074/jbc.M113.519264. Epub 2014 Feb 4.</citation>
    <PMID>24497637</PMID>
  </reference>
  <reference>
    <citation>Gordillo GM, Onat D, Stockinger M, Roy S, Atalay M, Beck FM, Sen CK. A key angiogenic role of monocyte chemoattractant protein-1 in hemangioendothelioma proliferation. Am J Physiol Cell Physiol. 2004 Oct;287(4):C866-73. Epub 2004 May 26.</citation>
    <PMID>15163622</PMID>
  </reference>
  <reference>
    <citation>Biswas A, Khanna S, Roy S, Pan X, Sen CK, Gordillo GM. Endothelial cell tumor growth is Ape/ref-1 dependent. Am J Physiol Cell Physiol. 2015 Sep 1;309(5):C296-307. doi: 10.1152/ajpcell.00022.2015. Epub 2015 Jun 24.</citation>
    <PMID>26108661</PMID>
  </reference>
  <reference>
    <citation>Biswas A, Pan X, Meyer M, Khanna S, Roy S, Pearson G, Kirschner R, Witman P, Faith EF, Sen CK, Gordillo GM. Urinary Excretion of MicroRNA-126 Is a Biomarker for Hemangioma Proliferation. Plast Reconstr Surg. 2017 Jun;139(6):1277e-1284e. doi: 10.1097/PRS.0000000000003349.</citation>
    <PMID>28538565</PMID>
  </reference>
  <reference>
    <citation>Atalay M, Gordillo G, Roy S, Rovin B, Bagchi D, Bagchi M, Sen CK. Anti-angiogenic property of edible berry in a model of hemangioma. FEBS Lett. 2003 Jun 5;544(1-3):252-7.</citation>
    <PMID>12782326</PMID>
  </reference>
  <reference>
    <citation>Biswas A, Clark EC, Sen CK, Gordillo GM. Phytochemical Inhibition of Multidrug Resistance Protein-1 as a Therapeutic Strategy for Hemangioendothelioma. Antioxid Redox Signal. 2017 Jun 10;26(17):1009-1019. doi: 10.1089/ars.2016.6881. Epub 2016 Nov 9.</citation>
    <PMID>27706944</PMID>
  </reference>
  <reference>
    <citation>Gordillo GM, Biswas A, Khanna S, Spieldenner JM, Pan X, Sen CK. Multidrug Resistance-associated Protein-1 (MRP-1)-dependent Glutathione Disulfide (GSSG) Efflux as a Critical Survival Factor for Oxidant-enriched Tumorigenic Endothelial Cells. J Biol Chem. 2016 May 6;291(19):10089-103. doi: 10.1074/jbc.M115.688879. Epub 2016 Mar 9. Erratum in: J Biol Chem. 2016 Jul 1;291(27):14394.</citation>
    <PMID>26961872</PMID>
  </reference>
  <reference>
    <citation>Bruckner AL, Frieden IJ. Hemangiomas of infancy. J Am Acad Dermatol. 2003 Apr;48(4):477-93; quiz 494-6. Review.</citation>
    <PMID>12664009</PMID>
  </reference>
  <reference>
    <citation>Dinehart SM, Kincannon J, Geronemus R. Hemangiomas: evaluation and treatment. Dermatol Surg. 2001 May;27(5):475-85. Review.</citation>
    <PMID>11359498</PMID>
  </reference>
  <reference>
    <citation>Drolet BA, Esterly NB, Frieden IJ. Hemangiomas in children. N Engl J Med. 1999 Jul 15;341(3):173-81. Review.</citation>
    <PMID>10403856</PMID>
  </reference>
  <reference>
    <citation>Metry DW, Hebert AA. Benign cutaneous vascular tumors of infancy: when to worry, what to do. Arch Dermatol. 2000 Jul;136(7):905-14.</citation>
    <PMID>10890993</PMID>
  </reference>
  <reference>
    <citation>Chiller KG, Passaro D, Frieden IJ. Hemangiomas of infancy: clinical characteristics, morphologic subtypes, and their relationship to race, ethnicity, and sex. Arch Dermatol. 2002 Dec;138(12):1567-76.</citation>
    <PMID>12472344</PMID>
  </reference>
  <reference>
    <citation>Bauman NM, McCarter RJ, Guzzetta PC, Shin JJ, Oh AK, Preciado DA, He J, Greene EA, Puttgen KB. Propranolol vs prednisolone for symptomatic proliferating infantile hemangiomas: a randomized clinical trial. JAMA Otolaryngol Head Neck Surg. 2014 Apr;140(4):323-30. doi: 10.1001/jamaoto.2013.6723.</citation>
    <PMID>24526257</PMID>
  </reference>
  <reference>
    <citation>Tozzi A. Oral Propranolol for Infantile Hemangioma. N Engl J Med. 2015 Jul 16;373(3):284. doi: 10.1056/NEJMc1503811.</citation>
    <PMID>26176393</PMID>
  </reference>
  <reference>
    <citation>Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J, Guibaud L, Baselga E, Posiunas G, Phillips RJ, Caceres H, Lopez Gutierrez JC, Ballona R, Friedlander SF, Powell J, Perek D, Metz B, Barbarot S, Maruani A, Szalai ZZ, Krol A, Boccara O, Foelster-Holst R, Febrer Bosch MI, Su J, Buckova H, Torrelo A, Cambazard F, Grantzow R, Wargon O, Wyrzykowski D, Roessler J, Bernabeu-Wittel J, Valencia AM, Przewratil P, Glick S, Pope E, Birchall N, Benjamin L, Mancini AJ, Vabres P, Souteyrand P, Frieden IJ, Berul CI, Mehta CR, Prey S, Boralevi F, Morgan CC, Heritier S, Delarue A, Voisard JJ. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med. 2015 Feb 19;372(8):735-46. doi: 10.1056/NEJMoa1404710.</citation>
    <PMID>25693013</PMID>
  </reference>
  <reference>
    <citation>Langley A, Pope E. Propranolol and central nervous system function: potential implications for paediatric patients with infantile haemangiomas. Br J Dermatol. 2015 Jan;172(1):13-23. doi: 10.1111/bjd.13379. Epub 2014 Dec 10.</citation>
    <PMID>25175684</PMID>
  </reference>
  <reference>
    <citation>Barlow CF, Priebe CJ, Mulliken JB, Barnes PD, Mac Donald D, Folkman J, Ezekowitz RA. Spastic diplegia as a complication of interferon Alfa-2a treatment of hemangiomas of infancy. J Pediatr. 1998 Mar;132(3 Pt 1):527-30.</citation>
    <PMID>9544915</PMID>
  </reference>
  <reference>
    <citation>Marczylo TH, Cooke D, Brown K, Steward WP, Gescher AJ. Pharmacokinetics and metabolism of the putative cancer chemopreventive agent cyanidin-3-glucoside in mice. Cancer Chemother Pharmacol. 2009 Nov;64(6):1261-8. doi: 10.1007/s00280-009-0996-7. Epub 2009 Apr 11.</citation>
    <PMID>19363608</PMID>
  </reference>
  <reference>
    <citation>Fang J. Bioavailability of anthocyanins. Drug Metab Rev. 2014 Nov;46(4):508-20. doi: 10.3109/03602532.2014.978080. Epub 2014 Oct 27. Review.</citation>
    <PMID>25347327</PMID>
  </reference>
  <reference>
    <citation>Manach C, Williamson G, Morand C, Scalbert A, Rémésy C. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr. 2005 Jan;81(1 Suppl):230S-242S. doi: 10.1093/ajcn/81.1.230S. Review.</citation>
    <PMID>15640486</PMID>
  </reference>
  <reference>
    <citation>Mahmood I. Application of allometric principles for the prediction of pharmacokinetics in human and veterinary drug development. Adv Drug Deliv Rev. 2007 Sep 30;59(11):1177-92. Epub 2007 Aug 16. Review.</citation>
    <PMID>17826864</PMID>
  </reference>
  <reference>
    <citation>Sharma V, McNeill JH. To scale or not to scale: the principles of dose extrapolation. Br J Pharmacol. 2009 Jul;157(6):907-21. doi: 10.1111/j.1476-5381.2009.00267.x. Epub 2009 Jun 5. Review.</citation>
    <PMID>19508398</PMID>
  </reference>
  <reference>
    <citation>Chang LC, Haggstrom AN, Drolet BA, Baselga E, Chamlin SL, Garzon MC, Horii KA, Lucky AW, Mancini AJ, Metry DW, Nopper AJ, Frieden IJ; Hemangioma Investigator Group. Growth characteristics of infantile hemangiomas: implications for management. Pediatrics. 2008 Aug;122(2):360-7. doi: 10.1542/peds.2007-2767.</citation>
    <PMID>18676554</PMID>
  </reference>
  <reference>
    <citation>Garzon MC, Drolet BA, Baselga E, Chamlin SL, Haggstrom AN, Horii K, Lucky AW, Mancini AJ, Metry DW, Newell B, Nopper AJ, Frieden IJ; Hemangioma Investigator Group. Comparison of infantile hemangiomas in preterm and term infants: a prospective study. Arch Dermatol. 2008 Sep;144(9):1231-2. doi: 10.1001/archderm.144.9.1231.</citation>
    <PMID>18794478</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>June 24, 2019</study_first_submitted>
  <study_first_submitted_qc>July 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2019</study_first_posted>
  <last_update_submitted>April 3, 2020</last_update_submitted>
  <last_update_submitted_qc>April 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Gayle Gordillo</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>miR126</keyword>
  <keyword>Pediaberry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemangioma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

